General
Preferred name
Mavacamten
Synonyms
MYK-461 ()
MYK461 ()
SAR439152 ()
Mavacamten (MYK-461) ()
SAR-439152 ()
Camzyos ()
P&D ID
PD060833
CAS
1642288-47-8
Tags
available
drug
Approved by
EMA
FDA
First approval
2022
Drug Status
investigational
approved
Drug indication
Obstructive hypertrophic cardiomyopathy
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Mavacamten (MYK-461) is an orally active myosin allosteric modulator that was developed by MyoKardia as a novel treatment for obstructive hypertrophic cardiomyopathy (HCM). In 2020 MyoKardia was bought by Bristol Myers Squibb. The compound interacts with both α and β cardiac myosins in vitro. Preclinical pharmacokinetics are reported in . Mavacamten attenuates hypertrophic and profibrotic gene expression in rodent models of HCM .
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
14
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
Guide to Pharmacology
MedChem Express Bioactive Compound Library
ReFrame library
Selleckchem Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
17
Molecular Weight
273.15
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
4
Ring Count
2
Aromatic Ring Count
2
cLogP
2.29
TPSA
66.89
Fraction CSP3
0.33
Chiral centers
1.0
Largest ring
6.0
QED
0.9
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
myosin inhibitor
Target
Myosin inhibitor
Myosin
MLCK
Pathway
cytoskeleton
Source data
